Joenja
What Joenja is used for
Joenja is indicated for the treatment of activated phosphoinositide 3-kinase delta syndrome (APDS) in adults and adolescents 12 years of age and older and weighing 45 kg or more.
Approved use, as published by the European Medicines Agency.
What the labels mean
- Orphan medicine: for a rare disease (affecting no more than 5 in 10,000 people in the EU).
- Approved under exceptional circumstances: full data cannot be collected, usually because the disease is very rare.
Key facts
- Brand
- Joenja
- Active substance
- leniolisib
- Disease area
- Primary Immunodeficiency Diseases
- Medicine group
- Antineoplastic agents
- ATC code
- L03AX22
- Marketing authorisation holder
- Pharming Technologies B.V.
- Authorised in the EU since
- 2026
Official information
In the USA
Same active substance: Joenja
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Joenja used for?
Joenja is indicated for the treatment of activated phosphoinositide 3-kinase delta syndrome (APDS) in adults and adolescents 12 years of age and older and weighing 45 kg or more.
What is the active substance in Joenja?
Joenja contains leniolisib.
Who makes Joenja?
The EU marketing authorisation holder is Pharming Technologies B.V..
Is Joenja an orphan medicine?
Yes. Joenja is designated an orphan medicine in the EU, for a rare disease (Primary Immunodeficiency Diseases).
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU